|Articles|August 16, 2012

ArisGlobal Announces New Central Coding and Dictionary Management System

ArisGlobal, a provider of solutions to the life science industry, has announced the immediate availability of agEncoder 2.1, its comprehensive coding and dictionary management system. 

The new release, certified by the Uppsala Monitoring Center to utilize the full features of WHO DRUG dictionary, offers new capabilities such as multi-lingual MedDRA support (including English, French, German, Italian, Japanese, Spanish, Portuguese, Czech, Hungarian and Dutch).  agEncoder also extends support of standardized MedDRA Queries (SMQs) and Custom MedDRA Queries (CMQs) including improved search capabilities and full impact analysis of new MedDRA versions.

Integrated with ArisGlobal’s pharmacovigilance and safety system (ARISg) and the company’s electronic data capture technology (agCapture), agEncoder offers comprehensive dictionary management and centralized coding with integrated workflow to ensure accurate and consistent coding of clinical terms.  Further functionality enhancements include improved search capability of the WHO-DD browser (e.g. search for active ingredients, search for preferred terms, generic terms, drug synonyms and umbrella search) and the use of eSignature.

Commented Mathias Poensgen, product manager. “agEncoder 2.1 serves the coding needs of both pharmacovigilance and clinical teams to improve the quality as well as the efficiency of their coding process.”

agEncoder 2.1 will be available to customers as a licensed, on-premise solution or as a hosted solution via agOnDemand™, ArisGlobal's comprehensive Software-as-a-Service (SaaS) delivery platform.

 


Related to this article

© C Davids/peopleimages.com - © C Davids/peopleimages.com - stock.adobe.com
The clinical research industry talks about patient-centeredness constantly but embeds it too late, too narrowly, and without clear ownership, and the cost shows up in enrollment failures, protocol deviations, and outcomes that don't reflect what patients actually care about.
The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data
This episode of The Human Side of Clinical Trials, hosted by Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., explores why training completion metrics like attendance and quiz scores fail to capture true study readiness, and how measuring both competence and confidence can reveal trial risks before enrollment even begins.